Literature DB >> 34045364

Where to go to in chlamydia control? From infection control towards infectious disease control.

Jan E A M van Bergen1,2,3, Bernice Maria Hoenderboom3, Silke David3, Febe Deug2, Janneke C M Heijne3, Fleur van Aar3, Christian J P A Hoebe4,5, Hanna Bos2, Nicole H T M Dukers-Muijrers6,7, Hannelore M Götz3,8, Nicola Low9, Servaas Antonie Morré10,11, Bjőrn Herrmann12, Marianne A B van der Sande13,14, Henry J C de Vries15,16, Helen Ward17, Birgit H B van Benthem3.   

Abstract

OBJECTIVES: The clinical and public health relevance of widespread case finding by testing for asymptomatic chlamydia infections is under debate. We wanted to explore future directions for chlamydia control and generate insights that might guide for evidence-based strategies. In particular, we wanted to know the extent to which we should pursue testing for asymptomatic infections at both genital and extragenital sites.
METHODS: We synthesised findings from published literature and from discussions among national and international chlamydia experts during an invitational workshop. We described changing perceptions in chlamydia control to inform the development of recommendations for future avenues for chlamydia control in the Netherlands.
RESULTS: Despite implementing a range of interventions to control chlamydia, there is no practice-based evidence that population prevalence can be reduced by screening programmes or widespread opportunistic testing. There is limited evidence about the beneficial effect of testing on pelvic inflammatory disease prevention. The risk of tubal factor infertility resulting from chlamydia infection is low and evidence on the preventable fraction remains uncertain. Overdiagnosis and overtreatment with antibiotics for self-limiting and non-viable infections have contributed to antimicrobial resistance in other pathogens and may affect oral, anal and genital microbiota. These changing insights could affect the outcome of previous cost-effectiveness analysis.
CONCLUSION: The balance between benefits and harms of widespread testing to detect asymptomatic chlamydia infections is changing. The opinion of our expert group deviates from the existing paradigm of 'test and treat' and suggests that future strategies should reduce, rather than expand, the role of widespread testing for asymptomatic chlamydia infections. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  chlamydia Infections; diagnostic screening programs; health services research; infection control; pelvic inflammatory disease

Year:  2021        PMID: 34045364     DOI: 10.1136/sextrans-2021-054992

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  6 in total

1.  Prevalence of Chlamydia trachomatis in the general population in Germany - a triangulation of data from two population-based health surveys and a laboratory sentinel system.

Authors:  Martyna Gassowski; Christina Poethko-Müller; Martin Schlaud; Andrea Sailer; Kerstin Dehmel; Viviane Bremer; Sandra Dudareva; Klaus Jansen
Journal:  BMC Public Health       Date:  2022-06-03       Impact factor: 4.135

2.  Prevalence estimates of genital Chlamydia trachomatis infection in Belgium: results from two cross-sectional studies.

Authors:  Natalie Fischer; Ilse Peeters; Sofieke Klamer; Marion Montourcy; Vicky Cuylaerts; Dominique Van Beckhoven; Irith De Baetselier; Johan Van der Heyden; Wim Vanden Berghe
Journal:  BMC Infect Dis       Date:  2021-09-14       Impact factor: 3.090

3.  Patterns of sexual behaviour associated with repeated chlamydia testing and infection in men and women: a latent class analysis.

Authors:  Inga Veličko; Alexander Ploner; Lena Marions; Pär Sparén; Björn Herrmann; Sharon Kühlmann-Berenzon
Journal:  BMC Public Health       Date:  2022-04-05       Impact factor: 3.295

4.  Crystal structure of an inorganic pyrophosphatase from Chlamydia trachomatis D/UW-3/Cx.

Authors:  Jasmine Maddy; Bart L Staker; Sandhya Subramanian; Jan Abendroth; Thomas E Edwards; Peter J Myler; Kevin Hybiske; Oluwatoyin A Asojo
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2022-02-28       Impact factor: 1.056

Review 5.  Controversies and evidence on Chlamydia testing and treatment in asymptomatic women and men who have sex with men: a narrative review.

Authors:  Nicole H T M Dukers-Muijrers; Ymke J Evers; Christian J P A Hoebe; Petra F G Wolffs; Henry J C de Vries; Bernice Hoenderboom; Marianne A B van der Sande; Janneke Heijne; Jeffrey D Klausner; Jane S Hocking; Jan van Bergen
Journal:  BMC Infect Dis       Date:  2022-03-14       Impact factor: 3.090

6.  Evaluating the impact and cost-effectiveness of chlamydia management strategies in Hong Kong: A modeling study.

Authors:  Sandra Montes-Olivas; Yaz Ozten; Martin Homer; Katy Turner; Christopher K Fairley; Jane S Hocking; Desiree Tse; Nicolas Verschueren van Rees; William C W Wong; Jason J Ong
Journal:  Front Public Health       Date:  2022-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.